title: Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
abstract: The BCR-ABL oncogenic tyrosine kinase causes chronic myeloid leukemia and is the target for imatinib therapy. During imatinib treatment, cells are selected in some patients with BCR-ABL kinase domain mutations that render decreased drug sensitivity. In addition, some patients express deletion mutants of BCR-ABL, apparently due to missplicing. Most commonly these deletion mutants lack a significant portion of the kinase domain that includes the P-loop. We describe a screen for such mutations in patients with CML and demonstrate that they are not oncogenic and are catalytically inactive. We hypothesized that coexpressing BCR-ABL deletion mutants has a dominant-negative effect on the native form through heterocomplex formation. However, upon coexpression of native and deletion mutant BCR-ABL in Ba/F3 cells, growth factor independence is maintained and signaling is activated normally. Despite this, these cells have increased imatinib sensitivity compared to cells expressing only native BCR-ABL. Thus, it will be important to investigate the prognostic impact of coexpression of deletion mutants in CML patients during imatinib treatment.
authors: Cell and Developmental Biology, Oregon Health & Science University, Portland, OR, USA.
authors: D W
authors: DW
authors: Sherbenou
authors: O
authors: O
authors: Hantschel
authors: L
authors: L
authors: Turaga
authors: I
authors: I
authors: Kaupe
authors: S
authors: S
authors: Willis
authors: T
authors: T
authors: Bumm
authors: R D
authors: RD
authors: Press
authors: G
authors: G
authors: Superti-Furga
authors: B J
authors: BJ
authors: Druker
authors: M W
authors: MW
authors: Deininger
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides; D049109:Cell Proliferation; D002478:Cells, Cultured; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015151:Immunoblotting; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D010766:Phosphorylation; D010879:Piperazines / Q000627:therapeutic use; D054448:Precursor Cells, B-Lymphoid / Q000378:metabolism / Q000473:pathology; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D017384:Sequence Deletion; D014443:Tyrosine / Q000378:metabolism
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D014443:Tyrosine; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl